$31.00
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

Movex asset has anti-inflammatory, analgesic, chondroprotective and regenerative effects. slows down the processes of damage to cartilage and bone resorption, restores cartilage, accelerates the formation of bone marrow in injuries, helps restore joint function.

Pharmacodynamics Glucosamine is a substrate for the construction of articular cartilage and stimulates the regeneration of cartilage tissue. Any adverse effect (disease, age-related metabolic disorders, injuries) reduces its synthesis and concentration in the connective tissue, which leads to a violation of the structure, function of the joints and the appearance of pain. Glycosaminoglycans and proteoglycans are part of the complex matrix that cartilage consists of.

Glucosamine is part of the endogenous cartilage glycosaminoglycans, stimulates the production of proteoglycans and increases the absorption of sulfate by articular cartilage.

Thus, glucosamine makes up for endogenous glucosamine deficiency. It takes part in the biosynthesis of proteoglycans and hyaluronic acid, thereby counteracting the progression of degenerative processes in the joints, spine and surrounding soft tissues; stimulates the formation of chondroitin sulfuric acid, normalizes the accumulation of calcium in bone tissue, helps restore joint function and the disappearance of pain.

Chondroitin sulfate is a high molecular weight mucopolysaccharide that affects calcium-phosphorus metabolism in cartilage. It slows down bone resorption, cartilage degeneration processes and reduces calcium loss. It has a chondroprotective effect under normal conditions and in the conditions of destruction of cartilage, stimulates the regeneration of cartilage, and has an anti-inflammatory, analgesic effect. Prevents compression of connective tissue, “lubricates” articular surfaces and normalizes the production of joint fluid.

Potassium diclofenac is an NSAID with analgesic, anti-inflammatory and antipyretic effects, has a rapid onset of action, which is especially important for the treatment of acute pain in inflammation. The mechanism of action is based on the inhibition of the synthesis of prostaglandins, which play a major role in the development of inflammation, pain and fever. The anti-inflammatory, analgesic and antipyretic properties of NSAIDs are associated with their ability to inhibit prostaglandin synthesis by blocking the synthesis of the COX enzyme. It reduces pain at rest and during movement, reduces manifestations of morning stiffness in joints, swelling of soft tissues, improves the functional state of the musculoskeletal system. Potassium diclofenac suppresses mainly the exudation phase, to a lesser extent, proliferation, reducing collagen synthesis and the associated tissue sclerosis.

Pharmacokinetics Glucosamine sulfate. The oral bioavailability of glucosamine is 25–26%. After distribution in tissues, the highest concentrations are determined in the liver, kidneys and cartilage. About 90% of glucosamine, which is ingested orally, is absorbed in the small intestine as a glucosamine salt and enters the liver through portal blood flow. A significant portion of the glucosamine that is absorbed is metabolized in the liver. It breaks down to urea, water and carbon dioxide. About 30% of the dose taken for a long time persists in connective tissue. It is excreted mainly by the kidneys and in very small amounts - with feces.

Chondroitin Sulfate. After a single dose of chondroitin Cmax in the blood plasma is reached after 3-4 hours, in the synovial fluid - after 4-5 hours. The concentration in the synovial fluid exceeds that in the blood plasma. The bioavailability of chondroitin sulfate is 13-15%. It is excreted by the kidneys for 24 hours.

Potassium diclofenac does not cumulate. WITHmax in blood plasma is achieved 2 hours after administration. Binding to plasma proteins - 99.7%. Penetrates into the synovial fluid. Systemic clearance of the active substance is 263 ml / min. T½ 1-2 hours from blood plasma. 60% is excreted by the kidneys as metabolites, less than 1% by the kidneys unchanged, the remainder as metabolites with bile.

Indications

  • Treatment of diseases of the musculoskeletal system, which are accompanied by signs of inflammation, pain, degenerative-dystrophic changes in the cartilage of the joints and spine, decreased joint mobility; osteoarthritis, periarthritis (including knee, hip joints, intervertebral osteochondrosis, spondylarthrosis), rheumatoid arthritis, fractures and injuries (to accelerate the formation of bone callus), post-traumatic inflammation of the soft tissues and musculoskeletal system (due to stretching, shock).

Application

C 18 years old. during the first 3 weeks, 1 tablet is prescribed 3 times a day. the treatment regimen is selected individually. tablets are taken orally with a small amount of liquid.

As prescribed by the doctor, treatment may be longer.

Contraindications

Hypersensitivity to the components of the drug. Do not use if you are allergic to shellfish. phenylketonuria, a tendency to bleeding, thrombophlebitis, diabetes mellitus, a stomach or intestinal ulcer, etc. during pregnancy and lactation. age to 18 years.

Side effects

Usually the drug is well tolerated.

From the gastrointestinal tract: epigastric pain, nausea, vomiting, diarrhea, cramping, dyspepsia, bloating, anorexia, gastrointestinal bleeding (bloody vomiting, melena, diarrhea with an admixture of blood), gastric and intestinal ulcers, which are accompanied or not accompanied by bleeding or perforation, aphthous stomatitis, glossitis, disorders of the esophagus, the occurrence of diaphragm-like strictures in the intestines, disorders of the lower intestines, such as nonspecific hemorrhagic colitis, exacerbation of nonspecific ulcerative colitis or Crohn’s disease, constipation, pancreatitis.

From the side of the central nervous system: headache, dizziness, drowsiness, impaired sensitivity, including paresthesia, memory impairment, disorientation, insomnia, irritability, cramps, depression, anxiety, nightmares, tremors, mental disorders, aseptic meningitis, etc.

From the sensory organs: visual impairment (blurred vision, diplopia), hearing impairment, tinnitus, taste impairment.

From the skin: skin rash, urticaria, bullous rashes, eczema, erythema multiforme, Stevens-Johnson syndrome, Lyell syndrome (acute toxic epidermal necrolysis), erythroderma (exfoliative dermatitis), hair loss, photosensitivity, purpura, including allergic purpura.

From the side of the kidneys: edema, acute renal failure, hematuria, proteinuria, interstitial nephritis, nephrotic syndrome, papillary necrosis.

From the liver: an increase in the level of aminotransferases in blood plasma, hepatitis, accompanied or not accompanied by jaundice, fulminant hepatitis, etc.

From the hemopoietic system: thrombocytopenia, leukopenia, hemolytic anemia, aplastic anemia, agranulocytosis.

Hypersensitivity reactions: systemic anaphylactic / anaphylactoid reactions, including arterial hypotension, vasculitis, pneumonitis.

From the cardiovascular system: palpitations, chest pain, hypertension, congestive heart failure, etc.

special instructions

Do not exceed recommended dose.

Use during pregnancy and lactation. The drug is not used during pregnancy and lactation.

Children. The drug is used in patients aged 18 years.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. The drug can affect the reaction rate, so it is not recommended to use it when driving vehicles or working with complex mechanisms.

Interactions

Increases the absorption of tetracyclines, reduces the absorption of penicillins and chloramphenicol.

Overdose

Symptoms: lethargy, drowsiness, nausea, vomiting, pain in the epigastric region, which are mainly reversible and disappear after symptomatic therapy. gastrointestinal bleeding, ag, arthritis, respiratory depression, coma are possible. Anaphylactoid reactions that occurred when taking the drug in therapeutic doses can also be the result of an overdose.

In case of an overdose, symptomatic and supportive therapy should be carried out. There is no specific antidote. It is recommended that patients with overdose symptoms in the first 4 hours after taking the drug artificially induce vomiting and / or take activated charcoal. Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may be ineffective due to the high ability to bind to proteins.

Storage conditions

At a temperature of 25 ° c.

Tags: Movex